August 2010
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p10
The article offers news briefs related to drug development in the U.S. The results of the clinical trial on the pharmacokinetics (PK) and safety of Levadex that orally inhaled migraine therapy are announced. The GSK 1838262/XP 13512 fails to demonstrate a statistically significant improvement as announced by GlaxoSmithKline and XenoPort. The Phase II trial of droxidopa of Chelsea Therapeutics receives a favorable outcome in the independent Data Monitoring Committee (DMC) review.


Related Articles

  • Making 'Histo'-ry? Antifolate Stalls, Chelsea's Droxi Avlive. Osborne, Randy // BioWorld Insight;6/21/2010, Vol. 18 Issue 25, p3 

    The article focuses on the statements made by Chelsea Therapeutics International Ltd. president Simon Pedder concerning the advancement of their experimentations with droxidopa after the delay of the antifolate CH-4051 Phase II trial in the U.S. Pedder said that regulators would like to see...

  • Chelsea's Droxidopa Flameout: Hope Alive for Second Phase III. Hollingsworth, Catherine // BioWorld Today;9/25/2009, Vol. 20 Issue 185, p1 

    The article reports on a decline in the value of shares owned by Chelsea Therapeutics International. Shares of the company declined by 61% after news that its most advanced production, droxidopa, for low blood pressure failed in a Phase II study. The drug is being tested in patients with...

  • Chelsea completes enrollment for Phase II hypotension trial.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p5 

    The article reports on the patient enrollment completed by Chelsea Therapeutics International Ltd. in its Phase II trial of Droxidopa in patients with intradialytic hypotension in the U.S. The trial is a multi-center, double-blind, placebo controlled study that compared 400 milligrams (mg) and...

  • In This Issue.  // Clinical Pharmacology & Therapeutics;Mar2015, Vol. 97 Issue 3, p195 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the debate on the concept of adaptive licensing (AL), Physiologically based pharmacokinetic modeling in drug discovery, and model-based clinical trial design.

  • CHELSEA THERAPEUTICS INITIATES CH-150 BIOEQUIVALENCE STUDY.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p4 

    The article reports that the CH-1504 bioequivalency study was initiated by the Chelsea Therapeutics International, Ltd. in Charlotte, North Carolina. The study was conducted at Swiss Pharma in Basel, Switzerland. It was noted that the preclinical and clinical data were expected to enable the...

  • CHELSEA GETS POSITIVE RESULTS FROM PHASE I CH-4051 TRIAL.  // Biotech Business;Jun2009, Vol. 22 Issue 6, p3 

    The article reports on the findings released by Chelsea Therapeutics International Ltd. from its Phase I trial of the orally bioavailale, non-metabolized antifolate CH-4051, in the Netherlands in April 2009. Findings indicate that the dose range of the drug considered safe and tolerable is up to...

  • CHELSEA REPORTS PRELIMINARY PHASE III DROXIDOPA DATA.  // Biotech Business;Nov2009, Vol. 22 Issue 11, p6 

    This article reports on the encouraging results obtained by Chelsea Therapeutics International Ltd. from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). Results of the study showed that Droxidopa was safe and...

  • CLINIC ROUNDUP.  // BioWorld Today;2/18/2009, Vol. 20 Issue 31, p9 

    This section offers news briefs related to several clinical trials. A second analysis of data from Phase III study of Chelsea Therapeutics International Ltd. showed that patients treated with Droxipoda had a reduction in the severity of symptoms associated with neurogenic orthostatic...

  • AAN Roundup.  // BioWorld Today;4/30/2012, Vol. 23 Issue 83, p8 

    The article presents a roundup of clinical trials reported at the American Academy of Neurology (AAN) meeting in New Orleans, Louisiana in April 2012. Baxter International Inc. presented Phase III data evaluating the safety and efficacy of Gammagard Liquid 10 percent to treat multifocal motor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics